Marijuana poses many challenges for researchers, law enforcement, and policy makers, challenges that fall into two fields: drug chemistry and toxicology. NIJ scientist Dr. Frances Scott joins this episode to explain the complications in drug chemistry and how difficulties defining marijuana lead to backlogs in crime labs around the country. NIJ Communications Assistant Josh Mondoro hosts. Read the transcript.
Reading and Resources from NIJ:
Other resources:
Correction: The article referenced by Dr. Scott as having been published in the 1950s was actually published in 1976. "A Practical and Natural Taxonomy for Cannabis" by Ernest Small and Arthur Cronquist, was published in TAXON in August 1976.
Marijuana poses many challenges for researchers, law enforcement, and policy makers, challenges that fall into two fields: drug chemistry and toxicology. NIJ scientist Dr. Frances Scott joins this episode to explain the complications in drug chemistry and how difficulties defining marijuana lead to backlogs in crime labs around the country. NIJ Communications Assistant Josh Mondoro hosts. Read the transcript.
Reading and Resources from NIJ:
Other resources:
Correction: The article referenced by Dr. Scott as having been published in the 1950s was actually published in 1976. "A Practical and Natural Taxonomy for Cannabis" by Ernest Small and Arthur Cronquist, was published in TAXON in August 1976.
SPEAKER 1: Welcome to Justice Today, the official podcast of the Department of Justice's Office of Justice Programs, where we shine a light on cutting edge research and practices, and offer an in-depth look at what we're doing to meet the biggest public safety challenges of our time. Join us as we explore how funded science and technology help us achieve strong communities.
JOSH MONDORO: Welcome back to the show, everyone. My name is Josh Mondoro. I'm your host for today, and we're going to be talking about marijuana. There are lots of conversations that are being had about marijuana: whether it's good, whether it's bad, whether it should be legal or illegal. We're going to take a bit of a different angle and look more closely at what is still unknown in this field, from a criminal justice standpoint. There are a lot of issues and questions that are still facing researchers who are working in this area, and we're going to try and come to an understanding of what those are today. Joining us is a returning guest to help us with this. She is a physical scientist with NIJ's Office of Investigative and Forensic Sciences. She holds a Ph.D. in chemistry from the George Washington University, and we are so happy to have her back on the show. Welcome back, Dr. Frances Scott.
FRANCES SCOTT: Thanks, Josh. Nice to be here.
JOSH MONDORO: All right. So this conversation is--we're going to kind of do it in two parts. So listeners stay tuned. But for part one, we're going to stick with drug chemistry. So there's kind of--from what you've told me, there are two halves to this conversation, so to speak. There's the drug chemistry aspect, and there is the toxicology aspect. So let's get some groundwork in here. Let's--can you define for us what those things are and what we will be talking about today?
FRANCES SCOTT: I can because I have to define them every time we get new leadership in, who may not be familiar with our kind of science. So drug chemistry is looking at the actual drug, the actual substance, so the plant or the vape oil, or the edible in the case of marijuana, those types of products. And so that's where you're looking at the actual components of the thing that you're going to take into your body. Toxicology is looking at the drug in your body. So there we're looking at some matrix from the body, some biological matrix. So oral fluid, urine, blood, et cetera.
JOSH MONDORO: So to someone like me who doesn't study and research this all the time, both of those sound very similar, almost like you can't have one without the other kind of. So is there a lot of overlap between those two, toxicology and drug chemistry?
FRANCES SCOTT: It's a good question. There's a lot of overlap there, but they tend to be looking at different questions. And in the case of a crime lab, it tends to--you know, you're looking at usually, perhaps supporting different types of charges. So you really are looking at two very different kinds of samples going to two different kind of branches of chemistry.
JOSH MONDORO: Awesome. So with that said, let's start in with marijuana from the drug chemistry side. And actually let's start here probably. What is marijuana? Let's define that upfront. What are we talking about?
FRANCES SCOTT: Right. Okay. So--and spoiler alert, we're going to be talking about marijuana, and we're going to be talking about hemp. And what you need to know is both of those are the same plant. So let's bear in mind, I'm not a botanist, but you know that we can breed plants to have particular characteristics that we want, right? You can breed your sunflowers to be taller and your corn to be more robust. And so in the case of marijuana and hemp, those are both cannabis sativa plants and one has been bred to have more pharmacologically active compounds. And the other is--has some of the other cannabinoids that are not going to have the same kind of mental effects.
JOSH MONDORO: And which one is which, just for--just for our listeners who maybe aren't familiar, which one is which?
FRANCES SCOTT: Right. So hemp is the one that it has been bred to…
JOSH MONDORO: Okay.
FRANCES SCOTT: …not get too high and whose fiber is extremely useful and sustainable. So that hemp is interesting…
JOSH MONDORO: Yeah.
FRANCES SCOTT: …from a farming point of view because it can take the place of some crops that are less sustainable.
JOSH MONDORO: Circling back quickly to the--I don't know if you use--so correct me if I'm wrong, I don't know if you used the word psychoactive, but I tend to associate Delta-9 THC with psychoactive stuff. Is that the compound you're talking about when you--when you--as part of the difference in these definitions, like the presence or absence of that compound?
FRANCES SCOTT: Yeah. So I kind of steer--I steered away from the compound, but yeah. So Delta-9 THC is the most known psychoactive compound. And it is the one that is generally most associated with kind of the known getting high effects of marijuana. So, yeah, that's the difference: is that hemp is going to have very low Delta-9 THC and higher CBD, which is cannabidiol. And marijuana is going to have the reverse. It's especially going to have a higher THC content.
JOSH MONDORO: Okay. Got you. With those definitions, right? There's a--few years ago a bill passed called the Farm Bill in 2018, right? Can you talk about what that bill was and like what its impact was on drug chemistry, maybe on these definitions and how that--yeah, because there's a lot there.
FRANCES SCOTT: Yeah. So the kind of general definitions that I just gave, you know, sort of are very qualitative, right? I said sort of high CBD, low THC is hemp and high THC, low CBD is marijuana.
JOSH MONDORO: Right.
FRANCES SCOTT: But how high and how low. And so what the Farm Bill did, and like I said, hemp is interesting from an agricultural point of view as a--as an actual crop. And so the Farm Bill legalized growing hemp…
JOSH MONDORO: Okay.
FRANCES SCOTT: …for those purposes. And so it needed to define more specifically what that is. And so I'm going to read you the definition from the Farm Bill. And so it says, “hemp is the plant, cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not”--hold on. We're not done yet. “With a Delta-9-tetrahydrocannabinol,” that's THC, “concentration of not more than 0.3% on a dry weight basis.”
JOSH MONDORO: Okay. That was a lot.
FRANCES SCOTT: Yeah. So--that was a lot. And it's challenging from a drug chemistry point of view. So lots of laws and bills are written by politicians and politicians…
JOSH MONDORO: Yeah.
FRANCES SCOTT: …scientists tend to be underrepresented in politics, is what I’ll say there. And so they do the best they can, but sometimes they use words that are not necessarily the types of words we would use or that are--where we all kind of understand what they mean.
JOSH MONDORO: Right.
FRANCES SCOTT: So for example, it talks about derivatives. So a derivative of that plant. So what does that mean from a scientific point of view? And so there’s a lot of discussion right now has been since the bill passed around some of these definitions, you know, any part of that plant including the cannabinoids with a Delta-9 THC concentration. So cannabinoids are sort of all of these: THC, CBD, CBN, CBG, there’s lots and lots and lots. All of those components of the plant, yeah. So are we talking about all of them, but then we’re talking specifically about Delta-9? Isomers is especially, that’s a very specific scientific word, but yeah. So an isomer is basically it’s a compound that has the same…
JOSH MONDORO: Uh-hmm. Okay.
FRANCES SCOTT: …weight and chemical formula, but it’s put together differently. So you had the same building blocks of it. You know, you have the same number of carbons and hydrogens, and oxygens, but you’ve assembled them slightly differently. So that’s an isomer.
JOSH MONDORO: So it creates a different compound?
FRANCES SCOTT: So it did--it’s a totally different compound, and it may behave differently, but by saying the isomers of that plant. But then we’re talking about Delta-9 THC. And so this has really been very complicated for drug chemists. And then in addition, because it used to be it’s all marijuana, you know, the--all the cannabis sativa plant that has a measurable THC, that you can see that there’s THC in, done and dusted, that’s marijuana, right? And so that you’re--you could sign out a lab report saying this is marijuana. Now, because we have quantified this very specific amount of Delta-9 THC on a dry weight basis, and it’s a percentage, that gets complicated. And so drug chemists were faced with needing to quantify THC concentrations, which they’ve never had to do before in order to be able to testify or sign a report that says this is marijuana, because we didn’t have to make those distinctions before.
And then if you thought that was all complicated, but wait, there’s more, right? So then we talk about derivatives and extracts. And so it’s the plant, any part of that plant including derivatives, extracts, et cetera. So now, think about all the products that you see at CVS, at the gas station that have a combination of letters on them, and they may say CBD, they may say Delta-8 THC, they may say full spectrum cannabis oil, you know. So now you’ve got all of these products. And what does that mean when you’re trying to figure out what the Delta-9 THC concentration is on a dry weight basis of something that’s a lotion or an oil?
JOSH MONDORO: Right. Right. Yeah. What--a quick--couple of questions came to my mind. One was, is there a difference or maybe what is the difference between like a derivative and an extract? Is it--and like it will--yeah. And I guess you kind of alluded to like that's the question, but…
FRANCES SCOTT: And that is kind of the question. And so, you know, how I might define that in a lab?
JOSH MONDORO: Right.
FRANCES SCOTT: Like derivative is not necessarily a term we would use very often unless we were back in calculus and doing those kinds of derivatives.
JOSH MONDORO: That’s what I thought, honestly, you know.
FRANCES SCOTT: Right.
JOSH MONDORO: I was a little--I wanted to get some clarification.
FRANCES SCOTT: So I think, you know, I can--I can sort of speculate from the way that it's written, you know, extraction, we kind of understand that process a little bit better and…
JOSH MONDORO: Yeah.
FRANCES SCOTT: …probably understand what that means there is that you're removing some compound out--compound or compounds, some components of that plant that's going to be an extract. And so I think a derivative could be similar. It's if you've done something to the plant or the components of the plant. But again, how far does that go? Like at what point is it no longer a derivative? At what point is it like a whole new thing?
JOSH MONDORO: Something new?
FRANCES SCOTT: Right.
JOSH MONDORO: Right. Right, right, right. That sounds very, very messy.
FRANCES SCOTT: Yes, it is.
JOSH MONDORO: Yeah, absolutely.
FRANCES SCOTT: And also by the way, 0.3% is very, very low. So I'll talk to you a little bit later about some research that we've had in this area, but…
JOSH MONDORO: Yeah.
FRANCES SCOTT: …and an article that we published. But it's low, and it's hard even if--even if someone is trying to--it's very easy to have, let's put it this way. It is very easy to have a plant that because of--because of growing seasons and whatever, might be just a tiny bit over that 0.3%, you know. And so that could be someone who illicit--now has an illicit plant that was not their intention.
JOSH MONDORO: Right. Not really their control, right? Well, I imagine it would be hard to control like in some ways.
FRANCES SCOTT: Yes.
JOSH MONDORO: Right?
FRANCES SCOTT: Very much so.
JOSH MONDORO: Right. Yeah. So that all--so the definition itself is very--has a lot of components to it. And it sounds like we're trying to define them still or not we, I'm not. People who are smarter than me are trying to define them, and it gets messy. Okay. That is very good. You had mentioned--when we were doing a little prep for this episode, you mentioned--we talked about isomers defining what those are, synthetic isomers came up. What are those? Because those are also at play, yes? And maybe a question for researchers.
FRANCES SCOTT: Yeah. And synthetic is challenging because synthetic sort of implies that it didn't come from the plant at all.
JOSH MONDORO: Right.
FRANCES SCOTT: And, you know, that it's--that it's made…
JOSH MONDORO: In a lab or something.
FRANCES SCOTT: …out of other things. Yes.
JOSH MONDORO: Yeah.
FRANCES SCOTT: And--but actually some of these isomers may be naturally occurring and they just may not be at the concentrations. Maybe in the--in the sort of raw plant material, they wouldn't have those concentrations. But once we get into all of these different kinds of products that are being made now…
JOSH MONDORO: Yeah.
FRANCES SCOTT: …they--you know, perhaps they've been concentrated or they may have been, again, not necessarily synthesized, but maybe a derivative of like maybe they--maybe they've been converted from a naturally occurring cannabinoid. So we've sort of--we've struggled with this in our community of like, "How do we refer to these things?" And at this point, we're kind of saying novel “non Delta-9 THC cannabinoids” and just kind of--because they're popping up. I mean, you're probably familiar with Delta-8, I mentioned that, that's come up a lot.
JOSH MONDORO: Yeah, yeah.
FRANCES SCOTT: Delta--and by the way, the Delta-9, just so you understand what that is a little bit, there's a ring of carbons in THC and the Delta-9 is a double bond in that ring that goes starting at the 9 carbon. So Delta-8 carbon, it--like Delta-8 THC is just you move that double bond one spot around in that ring structure. And Delta-10, you move it the other direction.
JOSH MONDORO: So is there a difference between all three of those other than the chemical structure? Like...
FRANCES SCOTT: Well, that’s another great question. And maybe…
JOSH MONDORO: Okay.
FRANCES SCOTT: …we'll probably talk about some of that in our other episode, because some of that gets into…
JOSH MONDORO: That gets into toxicology, right.
FRANCES SCOTT: Right. Like, are there different effects? And what does that mean from the--from the legal point of view, from the drug chemist point of view? Okay. Well, is it not Delta-9? Is it--is it a derivative of Delta-9? So where does that fall within the sort of the framework of is this thing hemp or is it marijuana? And what do we do when it's not a plant at all? It's something that came from a plant and now we're trying to backtrack and say, "Did this come from a hemp plant or a marijuana plant? And how in the world would you ever know that?"
JOSH MONDORO: Right. Right. Oh, my gosh. Definitions, what fun. So the--like, at this point, I'm thinking there must just be so much research being done just to try and figure out what all this means. Is that true? Like, is NIJ supporting research kind of in these areas or is there other stuff in the drug chemistry world that we are trying to figure out right now?
FRANCES SCOTT: Yeah. So there's a lot that we're trying to do to--you know, NIJ, we're always trying to support, particularly our practitioners. And state and local practitioners are our main sort of customers, and they're the ones who were really kind of hit the hardest with this. So, I think we've talked about before that the number one call for service, you know, that the things that come into a crime lab, a third of them come to drug chemistry. I mean, it's just…
JOSH MONDORO: Wow.
FRANCES SCOTT: …the most by a lot. Yeah. You know, drug chemistry and talks together is half of all calls for service, so it's a lot. And so you already had this huge, you know, sort of amount of casework coming in, and then now you've made it more complicated because you have to make this distinction. And so there's been a lot of research to try and figure out how can we give, you know, practitioners, particularly, tools to enable them to do that job efficiently and correctly and accurately. So, one line of research that we've had is with Dr. Rabi Musah at SUNY Albany. And so she's been looking at what's called the DART, which is Direct Acquisition in Real Time.
JOSH MONDORO: Okay.
FRANCES SCOTT: It’s a clever name.
JOSH MONDORO: Yeah.
FRANCES SCOTT: So, it’s a particular instrument. So a normal sort of drug chemistry run takes, let’s say 10 to 15 minutes, which doesn’t sound that…
JOSH MONDORO: To identify whatever’s in a certain substance or compound or whatever it is?
FRANCES SCOTT: To--yeah. To get your spectrum at the end and that’ll tell you what’s there and so forth. And by the way, when we’re talking about the hemp situation, then it can be a little more complicated because of course we’ve got to be able to tell the difference between the THC and the CBD, for example, which remember I said they’ve got the same mass and the same structure, so you got to be able to separate them or do something else. So, you know, 10 to 15 minutes doesn’t sound that long. But when—again, when you think about the volume of casework, that can be a lot, right? So DART is--it literally takes seconds. It’s, you know, dip a glass tube kind of into a solution or sort of rub your gummy against it or whatever, and you just put it directly into kind of the inlet or the stream of this instrument, and a spectrum comes out, I mean, literally within seconds.
JOSH MONDORO: Wow.
FRANCES SCOTT: So, it’s a little more complicated because of the THC CBD situation. But you can very quickly, first of all see if--is there a cannabinoid? Is there a THC or a CBD present? Very, very quickly. And then it’s relatively straightforward. She’s done a lot of work with some derivatizing agents. There’s that derivatives word again. So we need a little bit of a different thing. So we kind of--we’ll cause it to react with another chemical. And because of those slightly different structures, the way that they’re built, the new compound will sort of add onto it and it’ll add on kind of in two places to one and one to the other. So now they have different masses, and now we’re able to differentiate them by mass. And so it’s pretty straightforward to derivatize it.
JOSH MONDORO: So it kind of tags them, so to speak? And, like, makes it easier to just keep track of everything after you--afterwards?
FRANCES SCOTT: Yes.
JOSH MONDORO: Okay.
FRANCES SCOTT: Exactly.
JOSH MONDORO: That’s really cool.
FRANCES SCOTT: Yeah. And you’ve got different--right. Right. And so then--there--now, you’ve changed the masses. So now they don’t have the same mass. Now they don’t have the same structure because one’s going to have sort of two tags on it and one’s going to have one tag on it, let’s say. So once you’re able to do that, then you can very quickly separate those. And so she’s had really good luck with that quantification, calibrating that, and really being able to show some quantitative results, which of course we know is what we’re--what we’re all about now since we have hemp and marijuana. And she's been looking particularly at some of--not the plant, but some of these other products. And so she's looked at a whole array of gummies, and chocolates, and I want to say beverages, and a lot of these cosmetic type, you know, balms and lotions and things like that. And the issue with some of those is when we talk about some of the instruments that we traditionally use for chemistry in general, you have to be really careful of what you put on your instrument. And so the more stuff--so it will still work, so you don't gunk it up, right? So you literally…
JOSH MONDORO: Right.
FRANCES SCOTT: …don't put a bunch of, like, lotion into your half a million dollar instrument. Like, that's not great. That's…
JOSH MONDORO: Yeah, yeah.
FRANCES SCOTT: …not ideal. So, if you're going to, you know--and then--so then if you have to do more steps to extract it, there's that word again. But if you have to clean it up a lot, then again, that's adding to the time it takes to do that analysis.
JOSH MONDORO: And with so much demand, even that little…
FRANCES SCOTT: Exactly.
JOSH MONDORO: …amount of time adds up.
FRANCES SCOTT: Another line of research that we've had is with Brent Wilson at NIST, the one in Gaithersburg. And he was looking at the plants, and the differentiation of the plants. And then now he's also moved into some of those, what he's calling finished products. So again, some of those edibles and oil, a lot of the oils, you know, the vape oil is a big thing. And so, you know, so the vape stuff and a lot of these oily type things. Uh-hmm.
JOSH MONDORO: CBD oil too? Because some of those are, you know, I--I've heard, right? Like, some of those are like CBD, but oh, you might have some other stuff in them and it can get tricky, right?
FRANCES SCOTT: Yeah. That’s where they could go sort of full spectrum…
JOSH MONDORO: Yeah. Okay.
FRANCES SCOTT: … cannabinoids…
JOSH MONDORO: Okay.
FRANCES SCOTT: …or whatever. And some of them--so we just--so Brent and I co-wrote an article, it was in Police Chief Magazine, I think October. And look--talking about some of the results. And so just out of those first results out of--just out of the plants, before we even get into the finished products, you know, he'd bought over 50, I think different plant samples marketed as hemp. And when he actually did the analysis, he found that the vast majority of them were not legally hemp.
JOSH MONDORO: Oh, wow.
FRANCES SCOTT: They’re legally marijuana. Now…
JOSH MONDORO: That throws a wrench in things.
FRANCES SCOTT: That's if they're more than a point--yes, it does, right? And--but the problem is, I mean, it's not more than 0.3%. So some of these were like, 0.35%, 0.4%, okay? So they're really tiny amounts. So the implication--I mean, who can say? But the implication is, this is legitimate farmers legitimately trying to grow hemp. They're not trying to grow illicit marijuana and get you high because quite frankly, you'd have to smoke a joint the size of a telephone pole to get much off of that 0.35%, right?
JOSH MONDORO: Yeah. Right.
FRANCES SCOTT: So it’s just--it’s just a really hard line and it’s a really low line.
JOSH MONDORO: Yeah.
FRANCES SCOTT: So, I don't have better answers. But it's sort of fascinating where that 0.3% came from too. It seems to have come from, like, one mention hypothetically in an article from, like, the 1950s, and kind of got picked up and run with, because we don't know, because we've--because we've done things sort of qualitatively for a long time.
Correction: The article referenced above, "A Practical and Natural Taxonomy for Cannabis" by Ernest Small and Arthur Cronquist, was published in TAXON in August 1976.
JOSH MONDORO: Right.
FRANCES SCOTT: So…
JOSH MONDORO: So now there’s a switch, and so we’re kind of filling in that gap now.
FRANCES SCOTT: Exactly.
JOSH MONDORO: Yeah, that makes sense. That makes sense. Were there other projects that--I can't remember. Were there other projects that we're working on that you wanted to highlight?
FRANCES SCOTT: So, Dr. Musah is going to be starting a new project hopefully in January. And under our last round of funding, that's really exciting. Looking at some heavy metal complexes. So going away a little bit from her DART work, to do some more rapid kind of field level discrimination of hemp versus marijuana. And that's, you know, pretty critical too because there's--if you can presumptively say this is hemp, you know, this is someone's got a bunch of hemp, whatever, then you don't go down a route of, you know, potentially having someone possibly facing a charge that then later would be dropped after it goes through the full analysis at the lab, et cetera. You know, if you can--if you can do kind of presumptively put things into bins to start with, that is better for everybody.
JOSH MONDORO: Okay. So those NIJ researchers, like, they're doing fantastic work. I guess, how does that end up back in the field? Or, like, what's the trajectory to get that, I guess, like back in the field, helping people on the ground, like, do what they do?
FRANCES SCOTT: Right. So I'll start with Dr. Musah and some of the DART work that she's done. And so, you know, like I said, it's a much faster process. So the hope would be that labs that have a DART instrument could find a way to implement that into their casework processes and that would allow them to screen, you know, these potentially, you know, really large quantities of marijuana casework that are coming in much faster. And that would help them to kind of stay on top of that. Now, I will say that the downside sort of there is the DART is a pretty expensive, and not--so it's not everywhere, right? So not every lab has a DART. And not all of them have been successful in implementing it into casework. So we hope that that will allow the ones that do have it to implement it, maybe some others will be able to get it. But the work that Dr. Wilson's doing at NIST, that we've funded has a really--oh, sorry. National Institute of Standards and Technology.
JOSH MONDORO: Okay. Awesome.
FRANCES SCOTT: Yes.
JOSH MONDORO: Awesome.
FRANCES SCOTT: Our federal partners over there with standards and technology. And so, you can see--you can tell in the name, right? Like, standards, so they're very into process, which is great. And so that award and that research has had a very strong tech transfer element to it. So they have videos. I think they have a couple that are up right now where they're literally walking you through some of the steps of the procedures for the plant. They're working on that for the finished products. They've got some that walk through the math that's involved because when we talked about that whole dry weight thing and percentages and so forth. There's complications because THC acid, THCA, converts to THC. So that gets into, you know, is that part of this Delta-9 THC concentration and how do you calculate that? And so they are very focused on not only using real world samples to validate and to test, but also to have those procedures, and workflows and videos available, so that that can get out to as many labs as possible. And they're using technologies that are in a lot more crime labs. So they're using GC Mass spec, which is an instrument that's going to be really, really common in just about every drug chemistry section.
JOSH MONDORO: That makes sense. That's awesome. That's fascinating research. We'll have to come back and get some updates on these in the future.
FRANCES SCOTT: Yeah. Absolutely.
JOSH MONDORO: Thank you so much for the first half of our conversation, and talking us through the drug chemistry and marijuana, and all that I learned, as always, I learned a lot, so thank you.
FRANCES SCOTT: Fantastic. Thanks, Josh.
JOSH MONDORO: Thanks, listeners, for tuning in. Please follow us, if you like what you heard, follow us on Spotify, Apple, or wherever you get your podcasts. And stay tuned for part two where we dive into the toxicology.
SPEAKER 2: To learn more about today's topic or about NIJ, visit the links in the episode description and join us for new episodes every month.
Opinions or points of view expressed in this episode represent a consensus of the authors and do not necessarily represent the official position or policies of the U.S. Department of Justice. Any products and manufacturers discussed in this episode are presented for informational purposes only, and do not constitute product approval or endorsement by the U.S. Department of Justice.